Lagis Enterprise Co., Ltd. (6730) AI Stock Analysis

Lagis Enterprise Co., Ltd.

(TPEx:6730)

Select Model

Rating:69Neutral

Price Target:TWD 35.00▲(12.90% Upside)

Action:initiatedcoverage

Date:11/10/26

Strong profitability, balance-sheet quality, and attractive valuation are the main positives. These are offset by inconsistent free cash flow and technically weak momentum, producing an overall score of 69.

Positive Factors

Revenue and margin strengthRevenue expanded solidly from 2020 to 2025, with a sharp growth rebound in 2025 after a flat 2024. High gross margins of about 48–50% and EBIT margins of 17–19% indicate durable operating profitability, supporting reinvestment and resilience.

Negative Factors

Volatile and elevated leverageAlthough current leverage is moderate, debt has been volatile and remains elevated compared with the 2020–2022 baseline. This increases financial risk if operating conditions weaken, because interest, refinancing, or repayment demands could reduce flexibility and constrain future capital allocation.

Lagis Enterprise Co., Ltd. (6730) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 1.13B
Dividend Yield: 4.84%
Average Volume (3M): 10.21K
Price to Earnings (P/E): 7.8
Beta (1Y): 0.35
Revenue Growth: ―
EPS Growth: ―
Country: TW
Employees: 238
Sector: General
Sector Strength: 55
Industry: Medical - Instruments & Supplies

Lagis Enterprise Co., Ltd. Business Overview & Revenue Model

Company Description

Lagis Enterprise Co., Ltd. is a medical technology company focused on the development and global distribution of specialized devices for laparoscopic and endoscopic surgical procedures. Their comprehensive product portfolio includes trocars, single-p...

Lagis Enterprise Co., Ltd. Financial Statement Overview

Summary

Strong profitability and a solid balance sheet support the score, with 2025 revenue of 487.6 million, net income of 69.3 million, substantial equity, and reduced debt. Inconsistent free cash flow remains the primary weakness.

Income Statement

78Positive

Balance Sheet

82Very Positive

Cash Flow

62Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	492.35M	487.65M	454.36M	459.93M	442.19M	393.04M
Gross Profit	229.19M	236.20M	221.42M	218.89M	222.88M	178.28M
EBITDA	139.09M	130.66M	116.97M	112.36M	120.58M	92.31M
Net Income	68.69M	69.27M	68.24M	64.11M	71.04M	48.94M
Balance Sheet
Total Assets	1.17B	1.14B	1.09B	845.39M	658.75M	594.07M
Cash, Cash Equivalents and Short-Term Investments	113.93M	95.29M	69.20M	89.86M	128.52M	150.74M
Total Debt	262.54M	267.76M	394.37M	177.66M	9.03M	10.13M
Total Liabilities	427.49M	377.35M	506.34M	304.62M	124.49M	98.89M
Stockholders Equity	739.75M	761.99M	579.80M	540.77M	534.26M	495.18M
Cash Flow
Free Cash Flow	80.06M	39.64M	-202.05M	-148.51M	14.34M	66.72M
Operating Cash Flow	126.50M	131.68M	74.06M	77.49M	84.27M	96.24M
Investing Cash Flow	-47.84M	-91.37M	-275.80M	-226.00M	-69.75M	-29.52M
Financing Cash Flow	-10.56M	-14.23M	181.03M	109.89M	-36.77M	-30.71M

Lagis Enterprise Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6730 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:6730	69Neutral	TWD 1.17B	7.75	―	4.84%	―	―
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4109	45Neutral	TWD 1.21B	256.25	―	1.95%	13.00%	902.22%
TW:4198	42Neutral	TWD 1.10B	-28.07	―	―	―	―
TW:3710	30Underperform	TWD 1.35B	-1.51	―	―	-1.88%	-7106.53%

* General Sector Average

Performance Comparison

TW:6730 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6730	Lagis Enterprise Co., Ltd.	31.00	-9.45	-23.35%
TW:3710	ACON Holding Inc.	7.32	-4.97	-40.46%
TW:4109	Jia Jie Biomedical Co., Ltd.	10.25	-5.51	-34.96%
TW:4198	S&S Healthcare Holding Ltd.	48.00	10.00	26.32%
TW:6543	Perfect Medical Industry Co., Ltd.	16.55	-10.96	-39.85%
TW:6847	PuriBlood Medical Co.,Ltd.	70.40	0.11	0.16%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Lagis Enterprise Co., Ltd. AI Stock Analysis